文献速递乳腺癌

HER2阳性乳腺癌新辅助治疗全景:系统综述与网络Meta分析

Landscape of neoadjuvant therapy in HER2-positive breast cancer: a systematic review and network meta-analysis.
PubMed 文献 · Eur J Cancer · 2023-04-08

该系统综述与网络Meta分析纳入46项随机对照试验共11049例HER2阳性乳腺癌患者,评估32种新辅助方案。双靶向抗HER2联合化疗在病理完全缓解、无事件生存和总生存上显著优于曲妥珠单抗联合化疗,但心脏毒性风险更高;含蒽环类方案较不含蒽环类方案未显示更优疗效。

要点

  • 双靶向抗HER2联合化疗的病理完全缓解、无事件生存和总生存显著优于曲妥珠单抗联合化疗。
  • 双靶向抗HER2治疗的心脏毒性风险更高。
  • 含蒽环类化疗较不含蒽环类化疗未显示更优疗效,不含蒽环类方案中加用卡铂数值上疗效更优。

核心结论

  • 双靶向HER2阻断联合化疗是HER2阳性乳腺癌新辅助治疗的推荐选择,优选省略蒽环类而采用卡铂。

研究设计与样本

  • 系统检索Medline、Embase和Web of Science数据库,纳入符合特定标准的随机对照试验。
  • 采用频率学框架的随机效应模型网络Meta分析合并直接与间接证据。
  • 共纳入46项随机对照试验、11049例HER2阳性乳腺癌患者,评估32种不同方案。
  • 疗效终点为病理完全缓解、无事件生存和总生存,并分析选定的安全性终点。

主要发现

  • 双靶向抗HER2治疗(联合帕妥珠单抗或酪氨酸激酶抑制剂)联合化疗在病理完全缓解、无事件生存和总生存上显著优于曲妥珠单抗联合化疗。
  • 双靶向抗HER2治疗观察到更高的心脏毒性风险。
  • 含蒽环类化疗与不含蒽环类化疗相比,未与更优的疗效结局相关。
  • 在不含蒽环类的方案中,加用卡铂在数值上呈现更好的疗效结局。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The recommended preoperative approach for HER2-positive breast cancer is unclear. We aimed to investigate the following: i) what is the optimal neoadjuvant regimen and ii) whether anthracyclines could be excluded. METHODS: A systematic literature search in Medline, Embase and Web of Science databases was performed. Studies had to satisfy the following criteria: i) randomised controlled trials (RCTs), ii) enroled patients treated preoperatively for HER2-positive BC (breast cancer), iii) at least one treatment group received an anti-HER2 agent, iv) available information of any efficacy end-point and v) published in English. A network meta-analysis with a frequentist framework using random-effects model was used to pool direct and indirect evidence. Pathologic complete response (pCR), event-free survival (EFS) and overall survival (OS) were the efficacy end-points of interest, and selected safety end-points were also analysed. RESULTS: A total of 11,049 patients with HER2-positive BC (46 RCTs) were included in the network meta-analysis, and 32 different regimens were evaluated. Dual anti-HER2-therapy, with pertuzumab or tyrosine kinase inhibitors, combined with chemotherapy was significantly superior to trastuzumab and chemotherapy in terms of pCR, EFS and OS. However, a higher risk of cardiotoxicity was observed with dual anti-HER2-therapy. Anthracycline-based chemotherapy was not associated with better efficacy outcomes in comparison with non-anthracycline-based chemotherapy. In anthracycline-free regimens, the addition of carboplatin presented numerically better efficacy outcomes. CONCLUSION: Dual HER2 blockade with chemotherapy is the recommended choice as neoadjuvant therapy for HER2-positive breast cancer, preferably by omitting anthracyclines in favour of carboplatin.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Villacampa G, Matikas A, Oliveira M, et al. Landscape of neoadjuvant therapy in HER2-positive breast cancer: a systematic review and network meta-analysis. Eur J Cancer. 2023. PMID: 37142539. doi:10.1016/j.ejca.2023.03.042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。